Updates in the Diffuse Large B-Cell Lymphoma Treatment Landscape.

Area of Science:

• Oncology
• Hematology
• Immunotherapy

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Treatment advancements are crucial for improving patient outcomes.
• The COVID-19 pandemic has presented challenges in managing cancer patients.

Purpose of the Study:

• To summarize recent updates in DLBCL treatment presented at JADPRO Live Virtual 2021.
• To discuss the role of novel agents and chimeric antigen receptor (CAR) T-cell therapy in DLBCL management.
• To explore the impact of the COVID-19 pandemic on DLBCL patient care.

Main Methods:

• Review of presentations from JADPRO Live Virtual 2021.
• Discussion of emerging therapeutic strategies for DLBCL.
• Analysis of pandemic-related adaptations in clinical practice.

Main Results:

• Novel therapeutic agents show promise in DLBCL treatment.
• Chimeric antigen receptor (CAR) T-cell therapy is an evolving option for relapsed/refractory DLBCL.
• The COVID-19 pandemic necessitated modifications in treatment delivery and patient monitoring.

Conclusions:

• The landscape of DLBCL treatment is rapidly evolving with new therapies.
• CAR T-cell therapy offers a significant advancement for select DLBCL patients.
• Adapting treatment protocols during the COVID-19 pandemic was essential for continued patient care.